Cell and Gene Outsourcing

  1. MAD7 Gene Editing 9/30/2025

    A Class 2 Type V Cas9 nuclease, Mad7 is ideal for product development that relies on genome editing. 

  2. S-SELeCT™ One-Step Large Knock-In Technology 9/30/2025

    Simple, scalable genome engineering at the naturally occurring S-SELeCT™ safe harbor locus.

  3. TARGATT™ CHO Cells: Rapid, Stable CHO Cell Generation For Bioproduction 9/30/2025

    With our proprietary TARGATT™ technology for site-specific integration of large DNA fragments, we’ve developed a series of TARGATT™ “master” cell lines, including engineered CHO.

  4. TARGATT™ HEK293 Kits 9/30/2025

    Accelerate cell line development for library creation and protein expression with efficient TARGATT™ large knock-in technology.

  5. TARGATT™ iPSC Kits 9/30/2025

    Build cell-based models of disease and accelerate therapeutic development with TARGATT™ large knock-in technology in iPSCs.

  6. What Are The Keys To Making Rare Disease Drug Development Sustainable? 9/30/2025

    This roundtable weaves together diverse perspectives, providing a multifaceted look at what it will take to create a sustainable path forward in rare disease drug development.

  7. Manufacturing Strategies To Industrialize Autologous Therapies 9/30/2025

    Discover how a systematic approach to autologous cell therapy manufacturing can reduce costs, improve reliability, and accelerate access to life-changing treatments.

  8. Advanced iPSC Workflows: Accelerating Cell Therapy Development 9/30/2025

    Beyond offering our GMP-compliant iPS cells, we develop superior workflows for gene editing and differentiation to provide competitive platforms to our partners and accelerate their therapeutic programs.

  9. Improving Methodologies For iPSC Manufacturing And Differentiation 9/30/2025

    Learn how next-generation workflows are being developed to streamline iPSC manufacturing, enhance differentiation strategies, and overcome the hurdles of scalability and consistency.

  10. CDNPs Enable Versatile, Rapid, And Robust T Cell Expansion For Scalable CAR-T Manufacturing 9/25/2025

    Adopt next-generation, physiologic T cell activation strategies to enable faster, more consistent, and scalable CAR-T manufacturing that improves expansion, persistence, and patient access.